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CHAPTER ONE

INTRODUCTION

1.1

Tyrosinemia Type I
Hereditary Tyrosinemia type I (HT1) is an autosomal recessive disorder

characterized by an insufficient expression of the enzyme FAH, fumarylacetoacetate
hydrolase. It is due to this deficiency of FAH that individuals with HT1 are unable to
metabolize the amino acid tyrosine, which leads to a variety of harmful effects on the
organs of the body (de Laet et al. 2013). This high tyrosine concentration is accompanied
by toxic metabolites, which result from the defect in the tyrosine catabolic pathway. The
metabolites fumarylacetoacetate (FAA) and maleylacetoacetate (MAA) are primarily
responsible for the destruction of liver tissue, ultimately leading to liver cancer in HT1
patients (Lindblad et al. 1977). These metabolites accumulate to form another harmful
metabolite, namely succinylacetone (SA), in HT1 patients. The occurrence of liver cancer
as well as neurological crises are prevented by the drug treatment 2-[2-nitro-4(trifluoromethylbenzoyl) cyclohexane-1,3-dione (NTBC), which blocks the formation of
the toxic metabolites early in the tyrosine metabolic pathway.
The location of the FAH gene in humans is in the long arm of chromosome 15 in
the region q23-q25, and the defect in tyrosinemia type I is caused by multiple point
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mutations (Aponte et al. 2001; Phaneuf et al. 1991). The enzyme FAH is responsible for
the conversion of fumarylacetoacetate into fumarate and acetoacetate and is the terminal
enzyme necessary for tyrosine catabolism. This is the part of the tyrosine pathway that is
affected in tyrosinemia type I patients and results in an accumulation of the metabolites
proximal to this step such as FAA, MAA, and SA (Figure 1.1). This production of FAA,
MAA, and SA is characteristic of HT1 and is associated with a variety of negative effects
on the organs of the body. The acute form of tyrosinemia type I is associated with liver
failure that causes death early in life, while the chronic form presents with the eventual
development of liver disease and renal tubular defects characterized as de Toni Fanconi
syndrome (Aponte et al. 2001; Sun et al. 2000). HT1 patients present with varying
clinical symptoms, the most common of which are hepatocellular carcinoma (HCC),
hypophosphatemic rickets, and porphyria-like neurological crisis (Lindblad et al. 1977;
Mitchell et al. 1990). The life span of tyrosinemia type I patients has risen significantly as
a result of NTBC treatment.

1.2

Toxic Metabolite Production
The mutations in the gene FAH lead to the production of deleterious metabolites

that cause damage to the organs of tyrosinemia type I patients, specifically the liver and
kidneys. The lack of FAH expression in HT1 individuals leaves them unable to break
down tyrosine, and as a result of this, metabolites are formed upstream in the tyrosine
metabolic pathway. The metabolite fumarylacetoacetate (FAA) has been indicated to
contribute greatly to the occurrence of hepatocarcinoma in HT1 patients (Ashorn et al.
2006; Kubo et al. 1998). This metabolite has been shown to inhibit DNA glycosylases,
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Figure 1.1. The tyrosine catabolic pathway, illustrating the metabolic block in
tyrosinemia type I and the inhibitory effect of NTBC. Tyrosine is first synthesized by
the hydroxylation of phenylalanine by phenylalanine hydroxylase (PAH, EC 1.14.16.1).
Tyrosine can also be broken down from food, and further converted by the enzyme
tyrosine aminotransferase (TAT, EC 2.6.1.5) to 4-hydroxyphenylpyruvate. The drug
treatment 2-[2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione (NTBC) inhibits
the next step in the tyrosine pathway, which is the conversion of 4hydroxyphenylpyruvate into homogentisate by 4-hydroxyphenylpyruvate dioxygenase
(HPD, EC 1.13.11.27). NTBC treatment causes a lack of tyrosine breakdown which
results in hypertyrosinemia. Homogentisate dioxygenase (HGD, EC 1.13.11.5) further
oxidizes homogentisate to maleylacetoacetate (MAA), which is then isomerized into
fumarylacetoacetate (FAA) by maleylacetoacetate isomerase (MAI, EC 5.2.1.2).
Individuals with tyrosinemia type I are unable to break down fumarylacetoacetate into
fumarate and acetoacetate, the next step in the tyrosine metabolic pathway, as a result of
fumarylacetoacetate hydrolase (FAH, 3.7.1.2) deficiency.
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which are critical for the removal of mutagenic DNA base lesions (Bliksrud et al. 2013).
Considering the important role of DNA glycosylases in removing oxidative base lesions
and the inhibitory effect of FAA on this process, the occurrence of hepatocellular
carcinoma in HT1 patients could result from increased mutagenesis. FAA has also been
proposed to cause direct hepatic injury by stimulating the release of cytochrome c from
mitochondria, which further causes apoptosis of cells (Kubo et al. 1998). The caspase
cascade is activated upon release of cytochrome c from mitochondria and leads to
fragmentation of the nucleus, and this process can be inhibited by caspase inhibitors
(Kubo et al. 1998; Sun et al. 2000). The activation of the AKT survival pathway has also
been associated with hepatic stress caused by a lack of FAH expression in HT1 patients
(Orejuela et al. 2008). It is through these processes that FAA has been implicated to
cause direct damage to liver tissue, and along with maleylacetoacetate, lead to
hepatocellular carcinoma in tyrosinemia type I patients (Figure 1.2).
Liver and kidney dysfunction are the most common symptoms presenting in HT1
patients, with cirrhosis of the liver and hepatocarcinoma the most profound effects (de
Laet et al. 2013). The enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD) is
responsible for the second step in tyrosine catabolism and converts 4hydroxyphenylpyruvate into homogentisate. This enzyme is highly expressed in both the
liver and kidneys, which helps to explain why these organs are affected the most in HT1
patients considering that the toxic metabolites build up there as a result of FAH
deficiency (Ashorn et al. 2006; Lindblad et al. 1977). The activity of HPD is inhibited by
the drug treatment NTBC, and results in the prevention of toxic metabolite production.
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Figure 1.2. The toxic metabolites that are produced as a result of the lack of
functional FAH protein expression in hepatocytes could lead to endoplasmic
reticulum (ER) stress, that could further activate several signaling cascades. The
metabolite fumarylacetoacetate (FAA) is proposed to activate the PKC,
Ras/Raf/MEK/ERK, and PI3K/AKT pathway which are related to mitochondrial
apoptosis through the release of cytochrome c. The activation of the transcription factor
FKHR, the phosphorylation of Bad, and the inactivation of glycogen synthase kinase 3
beta (GSK3B) are all associated with the inhibition of mitochondrial apoptosis through
the activation of the AKT survival pathway. This figure was modified from Tanguay et
al. 2017.
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1.3

NTBC Treatment
The drug 2-[2-nitro-4-(trifluoromethylbenzoyl) cyclohexane-1,3-dione, known as

Nitisinone (NTBC), is a potent inhibitor of the mammalian enzyme 4-hydroxyphenyl
pyruvate dioxygenase (HPD) (Lock et al. 2014). NTBC inhibits the conversion of 4Hydroxyphenylpyruvate into homogentisate by HPD, which further leads to an inhibition
of tyrosine metabolism. The use of NTBC treatment in tyrosinemia type I leads to
hypertyrosinemia, causing increased levels of tyrosine concentrations within the body
(Bendadi et al. 2014). An increase in survival rate has occurred since the introduction of
NTBC, due to the effectiveness of the drug in preventing liver damage from metabolite
production. As a result of the success of using NTBC in HT1, it has been suggested to be
used as a treatment option for another disorder associated with the tyrosine metabolic
pathway, namely alkaptonuria, which is characterized by a lack of expression of
homogentisate dioxygenase (HGD) (Lock et al. 2014). This lack of HGD causes a
buildup of homogentisic acid within the body, which further causes damage to cartilage
and can lead to osteoarthritis as well as joint issues.
The treatment regimen for HT1 patients was revolutionized when the herbicide
NTBC was shown to prevent the accumulation of harmful metabolites and their
associated damage to the body. The current treatment for HT1 patients includes the drug
NTBC and restriction of tyrosine and phenylalanine intake to reduce blood tyrosine levels
(Al-Dhalimy et al. 2002). The combination of NTBC treatment and modification of
tyrosine intake in a mouse model of HT1 was not sufficient to prevent the occurrence of
hepatocellular carcinoma, indicating that NTBC treatment must be closely monitored in
HT1 patients in order to prevent HCC (Al-Dhalimy et al. 2002). Succinylacetone has
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been shown to be elevated in HT1 patients after liver transplantation, while
administration of NTBC treatment leads to the prevention of succinylacetone formation
and low plasma levels of SA (Bartlett et al. 2013). The only treatment options available
for HT1 patients before NTBC was introduced were liver transplantation and dietary
modification of tyrosine and phenylalanine intake. Once daily dose of NTBC treatment
is sufficient to counteract the production of succinylacetone and is proposed to improve
the patients compliance to the drug (Schlune et al. 2012). Although treatment with NTBC
has proven to be effective in inhibiting the toxic metabolite accumulation, HT1 patients
should continue to be monitored for HCC (Ashorn et al. 2006).

1.4

Neurological Issues in HT1: Porphyria-Like Syndrome
Neurological issues have been a recurrent problem in HT1 patients on a restricted

diet of tyrosine and phenylalanine and are associated with a buildup up the metabolite
succinylacetone. Porphyria-like syndrome and peripheral neuropathy have long been
characterized as neurological crisis in HT1 patients, and stem from the formation of
succinylacetone. It is referred to as porphyria-like syndrome because it resembles the
symptoms present in acute intermittent porphyria. Tyrosinemia type I is characterized by
high levels of tyrosine and its associated metabolites such as FAA, MAA, and
succinylacetone. Analyzation of these metabolites, particularly succinylacetone, by
tandem mass spectrometry in dried blood spots allows for the diagnosis of HT1 to be
confirmed (De Jesus et al. 2014; Fernandez-Lainez et al. 2014). It was through the
increased excretion of these metabolites, but specifically succinylacetone, in the serum
and plasma of HT1 patients that enabled Lindblad et al. (1997) to suggest that the
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primary genetic defect in HT1 is due to a lack of fumarylacetoacetate hydrolase
expression.
Fumarylacetoacetate and maleylacetoacetate are rapidly converted into
succinylacetone, and for this reason HT1 patients have a high level of this toxic
substance. Succinylacetone has been shown to produce disastrous effects on the organs of
the body and cause elevated levels of the heme precursor δ-aminolaevulinic acid (δ-ALA)
in tyrosinemia type I due to its inhibitory effect on porphobilinogen synthase (δ-ALA
dehydratase) (Sassa and Kappas 1983). This inhibition of δ-ALA dehydratase leads to
increased levels of δ-ALA because it is responsible for its degradation (Sassa and Kappas
1983). The amino acid glycine as well as succinyl-CoA from the citric acid cycle are used
to produce δ-ALA, and it is necessary for the initiation of the heme biosynthesis pathway.
Delta-aminolaevulinic acid is a heme precursor that has been found to produce
porphyria-like syndrome as well as neurological complications in HT1. It has been
indicated that δ-ALA exposure can block the synthesis of peripheral myelin formation as
well as prevent the maintenance of peripheral nerves by altering glial cell function
(Felitsyn et al. 2008). The pro-oxidant properties of δ-ALA have been suggested to
contribute to oxidative damage of myelinating glial cells in the peripheral nervous
system, and δ-ALA exposure has also been shown to cause demyelination as well as
axonal degeneration of peripheral nerves (Felitsyn et al. 2008; Mitchell et al. 1990). The
effects of δ-ALA have been attributed to the peripheral neuropathy and neurological
crisis that are associated with tyrosinemia type I. The neurological crises can be
prevented in HT1 due to treatment with NTBC, but recent reports have suggested
neuropsychological problems in HT1 patients on long-term NTBC treatment.
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1.5

Neurocognitive Issues in HT1
Neurocognitive issues have been observed in tyrosinemia type I patients including

impairments in social and emotional cognition, executive functioning, as well as lower IQ
scores compared to healthy controls (Bendadi et al. 2014; van Ginkel et al. 2016; de Laet
et al. 2011). Executive functions are a set of mental skills that are used in order to
organize thoughts and actions into behaviors and are integrated by the frontal lobe.
Individuals with HT1 show impairments in working memory in comparison to healthy
controls, and also display problems in distinguishing between different facial expressions,
which indicates impairments in social behavior (van Ginkel et al. 2016). There have been
recurrent observations of neurocognitive issues in HT1 patients recently, but the exact
mechanism behind these problems as well as the exact neurocognitive profile of HT1
patients remains unclear.
Social cognition requires the analysis of many different behaviors and has been
implicated to be altered in many psychiatric disorders. Social as well as cognitive
functions are dependent upon proper myelination of the CNS. Social experience has been
observed to cause activation of prefrontal cortex (PFC) neurons through an activitydependent mechanism (Toritsuka et al. 2015). Myelination has been suggested to act as a
mechanism for activity-dependent nervous system plasticity, with increased social
interactions leading to changes in synapse structure (Fields 2005; Nave 2010). The
prefrontal cortex is the area of the brain associated with the regulation of aspects of social
behavior, with alterations in the circuitry of this region associated with certain
neurodevelopmental disorders (Bicks et al. 2015; Toritsuka et al. 2015). The frontal
regions of the cerebral cortex are the last the undergo myelination and continue to go
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through development until the third decade of life (Fields 2010). The social behavior and
cognitive problems seen in HT1 patients could result from defects in the myelination
process.
Prefrontal cortex myelination has also been suggested to be influenced by
microbiota, with alterations in the microbiome associated with neurodevelopmental
issues (Hoban et al. 2016) (Figure 1.3). The microbiota-gut-brain axis is a bidirectional
communication that occurs between the brain and the microbiota within the gut. It has
been found using germ-free mice that the lack of intestinal microbiota actively affects the
brain and aspects of cognition, social behavior, as well as anxiety-like behavior
(Luczynski et al. 2016). One disorder that has been associated with altered microbiota is
autism spectrum disorder (ASD), which is characterized by impaired social cognition and
abnormal behavior (Hoban et al. 2016; Luczynski et al. 2016; Mudd et al. 2017). Serum
cortisol has also been shown to play a role in the microbiota-brain axis, in that it mediates
the relationship between the brain-specific metabolite N- acetylaspartate (NAA) and fecal
Ruminococcus in pigs (Mudd et al. 2017). This relationship suggests a direct link
between a specific neurometabolite and fecal microbiota, which further strengthens the
hypothesis that particular bacteria can influence the communication between the gut and
the brain. A relationship of serum cortisol, NAA, and Ruminococcus has also been
identified independently in ASD, which indicates a possible mechanism of all three in the
development of the disorder (Mudd et al. 2017). These results provide evidence that the
gut-brain axis could be important in the onset of neurodevelopmental disorders such as
ASD, and could have implications in disorders such as tyrosinemia type I.
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Figure 1.3. The relationship between disturbed microbiota in the gut and the effects
on the brain is shown through the upregulation of various myelin genes. Germ-free
mice have been found to have increased thickness of myelin sheaths as a result of the
upregulation of myelin genes such as myelin basic protein (MBP), proteolipid protein
(PLP) and the major myelin regulatory factor (Myrf). Altered oligodendrocyte and
neuron function is thought to contribute to the thickening of the myelin sheath through
MAP-kinase signaling. Figure modified from Hoban et al. 2016.
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1.6

Central Nervous System Myelination
Central nervous system (CNS) myelination is a highly regulated process that

begins early in development and continues throughout adulthood. Proper development as
well as maintenance of myelin is critical for action potential propagation and is further
necessary for normal cognition. Myelination of the CNS is the process by which axons
are enveloped by an electrical insulating layer termed myelin, which allows for quick
conduction velocity along an axon and increased speed of action potentials (Nave and
Werner 2014). Myelin is a lipid-rich substance that is composed of a variety of proteins
and lipids, with myelin basic protein (MBP) and proteolipid protein (PLP) forming a
majority of its protein composition (Jahn et al. 2009). Axons are covered by several
concentric layers of this fatty substance by oligodendrocytes, with spaces in between
each myelin segment called Nodes of Ranvier (Figure 1.4). It is through these nodes of
Ranvier that action potentials can be propagated along an axon through a process called
saltatory conduction. Action potentials are able to jump from one node of Ranvier to
another along an axon, which increases the conduction velocity of the neuronal impulse.
Alterations in myelination can further disrupt the propagation of neuronal impulses and
cause impaired behavior or cognition.
Oligodendrocytes are responsible for myelination of the CNS, while Schwann
cells are responsible for peripheral nervous system (PNS) myelination (Michalski and
Kothary 2015). The CNS is composed of neurons that are specialized to conduct neuronal
impulses and glial cells which act to maintain, support, and influence neurons.
Myelination of the CNS is critical for normal information
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Figure 1.4. The proposed model of myelination illustrating the growth zone of an
oligodendrocyte attached to the axon that will be myelinated. The first step in the
process of myelination is the contact of an oligodendrocyte to an axon, wherein a growth
zone is formed (a). Cytoplasmic channels are then formed within the zone to provide a
source of communication between the inner and outer membrane (b). It is through the
movement of the inner membrane under the outer membrane that the compact sheaths of
myelin are formed (c). The process of myelination stops once the axon is covered with
the proper amount of myelin, and the cytoplasmic channels close as soon as myelination
is complete (d). Figure modified from Bercury and Macklin 2015.
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processing, with synchronous neuronal impulses necessary for proper cognition (Fields
2008). Myelination of the CNS has been shown to be influenced by both positive and
negative regulators, and myelin alterations have been shown in mice with genetic
modifications in several different genes important in the production of myelin
(Ahrendsen and Macklin 2013). Myelin must also be maintained within a certain range in
order to ensure normal cognitive abilities, with either a dramatic increase or decrease in
myelination levels associated with neurocognitive impairments.

1.7

White matter
Half of the human brain is made up of white matter and is composed of

myelinated axons, with the electrical insulating sheath of myelin causing the white
coloration. Organization of the circuitry of white matter within the brain has been
implicated to be critical for several aspects of brain function. White matter is important
for controlling the speed of neuronal impulses, with the synchronicity of these signals
necessary for proper cognitive performance (Fields 2008). White matter structure is
dynamic and can be altered through activity-dependent mechanisms, with abnormal white
matter integrity associated with problems in information processing and learning (Fields
2010). It has also been found that situations of social isolation can mimic the effects of
certain neurodevelopmental disorders in mice through impairing the myelination process
of the prefrontal cortex (Liu et al. 2012). These results indicate that if the myelination
process of white matter is disrupted, that neuropsychiatric disorders can arise.
Alterations in white matter structure are observed in various psychiatric disorders,
an example of which is reduced white matter in patients with major depressive disorder in
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the area associated with emotional regulation, the superior longitudinal fasciculus (Shen
et al. 2017). This result suggests that white matter structure can be changed as a result of
neuropsychiatric issues, and further indicates that white matter is critical for normal
neurocognitive outcome. A brain CT scan of an HT1 patient has shown bilateral cerebral
atrophy, indicating an association of the disorder with the white matter structure of the
brain (Rashad and Nassar 2011). Impairments in myelination of the globus pallidus has
also been observed in an HT1 patient upon brain MRI analysis (Sener 2005). These
results suggest that white matter is susceptible to damage in patients with HT1, with the
mechanisms behind this abnormal myelination unclear.

1.8

Phenylketonuria
Another inherited disorder that is associated with neurocognitive impairments is

phenylketonuria (PKU), which presents as the opposite biochemical profile to
tyrosinemia type I and is caused by a low expression of the enzyme phenylalanine
hydroxylase (PAH) (Antenor-Dorsey et al. 2013). The deficiency of PAH leads to a lack
of tyrosine and its associated metabolites as well as an elevated level of phenylalanine,
since PAH is responsible for converting phenylalanine into tyrosine. Patients with PKU
have been shown to have diffuse brain pathology and demyelination of white matter,
which has been proposed to be more severe with higher phenylalanine levels and can be
reversed through the maintenance of a low phenylalanine diet (Anderson and Leuzzi
2010). Untreated PKU leads to severe neurological issues and intellectual disabilities,
with dietary regulation of phenylalanine as the primary treatment for PKU. Although
dietary treatment for PKU prevents these symptoms, early-treated PKU patients present
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with issues in psychological and executive functioning (Antenor-Dorsey et al. 2013;
Christ et al. 2016; Hood et al. 2015). Although the exact source of the neurocognitive
problems in patients with PKU is not clear, it has been suggested that dopamine
deficiency and white matter pathology observed in PKU could contribute to the
psychological impairments (Anderson and Leuzzi 2010; Antenor-Dorsey et al. 2013).
The white matter integrity of patients with PKU has been investigated using mean
diffusivity (MD) as a measure from diffusion tensor imaging (DTI), which is an advanced
MRI that utilizes water molecule movement throughout the brain to measure the
microstructure of white matter. It has been shown using DTI that patients with PKU have
widespread lowered MD in their white matter in comparison to control groups (AntenorDorsey et al. 2013; Hood et al. 2015). This indicates that there is a decrease in the rate of
water molecule movement throughout the brains of patients with PKU in comparison to
the brains of control patients, and further confirms alterations in the structure of white
matter. High blood phenylalanine levels have also been suggested to contribute to
decreases in MD as well as impaired executive functioning (Antenor-Dorsey et al. 2013;
Hood et al. 2015). Recent studies have also shown abnormalities in grey matter volume in
patients with PKU, with decreased grey matter volume observed in the parietal and
occipital cortex of patients with PKU compared to the non-PKU patients (Christ et al.
2016). These results suggest that the altered white and grey matter structure seen in
patients with PKU could be associated with the metabolic control of phenylalanine as
well as tyrosine.
Phenylketonuria is characterized by elevated phenylalanine concentrations and
decreased tyrosine concentrations as a result of PAH deficiency. The low tyrosine
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concentration in PKU also leads to dopamine deficiency, which has been suggested as a
possible cause for the neurocognitive problems that affect patients with PKU (Anderson
and Leuzzi 2010; Andtenor-Dorsey et al. 2013). Tyrosinemia type I, however, leads to an
increase in dopamine synthesis as a consequence of increased tyrosine concentrations
within the body. Dopamine synthesis requires the hydroxylation of tyrosine to L-DOPA
by the enzyme tyrosine hydroxylase. The large neutral amino acid transporter (LAT-1) is
responsible for transporting amino acids across the blood brain barrier (BBB) and into the
brain. Amino acids exhibit competitive transport into the brain, with an increase in
concentration of a particular amino acid leading to a decrease in the transport of other
amino acids (de Laet et al. 2011). The exact effects of high levels of phenylalanine or
tyrosine on the brain are undetermined, but increased tissue levels of a particular essential
amino acid have been proposed to lead indirectly to brain damage (Menkes 1967).

1.8

Purpose of study and theory for cognitive defects in HT1
Treatment with NTBC for tyrosinemia type I results in increased tyrosine

concentrations within the body. NTBC stops the production of the harmful metabolites
that are characteristic of HT1 by acting upstream in the tyrosine metabolic pathway, and
thereby causes hypertyrosinemia through its inhibition of HPD. This disorder has recently
become associated with poor neurocognitive outcome in patients on long-term NTBC
treatment, with the exact source of these issues uncertain. The low life expectancy of
HT1 patients before treatment with NTBC was introduced can be attributed mainly to the
liver dysfunction caused by harmful metabolite accumulation. Considering that a priority
in the early treatment of HT1 patients was keeping them alive, it is possible that any
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neuropsychological problems caused by the disease process of tyrosinemia type I were
not able to be observed. However, there were no reports of cognitive issues in HT1
patients before the introduction of NTBC treatment (Mitchell et al. 1990).
Treatment with NTBC leads to high levels of tyrosine within the body, which
could further cause increased transport of tyrosine into the brain through LAT-1.
Considering that tyrosine is a precursor for dopamine, increased tyrosine concentrations
could also cause increased dopamine synthesis within the brain (de Laet et al. 2011).
Tyrosine and phenylalanine exhibit competitive transport into the brain through the LAT1 transporter, which means that high levels of tyrosine in NTBC-treated animals could
interfere with the transport of phenylalanine (Figure 1.5). The brains of NTBC-treated
mice, therefore, may have an excess of transport of tyrosine and a deficiency of
phenylalanine transport. Neurotransmitters must be kept at an optimal range, or
neurological dysfunction will occur. The neurocognitive impairments observed in HT1
patients could have a source in elevated plasma tyrosine concentrations, that could in turn
alter dopamine synthesis within the CNS.
Studies with tyrosinemia type I mice have shown impaired learning and memory
in diseased mice on NTBC treatment in comparison to wild-type mice on NTBC,
suggesting that the neurocognitive issues stem from the disease process of tyrosinemia
type I (Hillgartner et al. 2016). In order to determine the social behavior deficits observed
in patients with HT1, Crawley’s three-chambered sociability test will be used to compare
the sociability of mice with HT1 to wild-type mice. The olfactory abilities, plasma
tyrosine levels, as well as cerebral cortex myelination will also be measured. The
metabolites produced in tyrosinemia type I, such as FAA, MAA, SA, and δ-ALA, could
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Figure 1.5. The proposed model of the possible negative effects of NTBC treatment,
δ-ALA, FAA, high tyrosine, low phenylalanine, and high dopamine concentrations
on the brain is shown above. The precise role of NTBC, δ-ALA, and FAA on brain
function in patients with HT1 remains to be confirmed, as well as the role and expression
of the enzyme FAH in the brain. The high tyrosine concentration that is caused by NTBC
treatment could lead to increased dopamine synthesis within the brain, as well as alter the
concentrations of other neurotransmitters due to the lack of phenylalanine transport
through LAT-1. The effects of these compounds could be individually or collectively
contributing to the neurocognitive issues observed in HT1 patients.
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be collectively or individually affecting the brain through either their toxicity or effects
on other important compounds. These metabolites could cause altered brain biochemistry
that could provide a mechanism for the impaired cognition and social behavior observed
in HT1 patients.
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CHAPTER TWO

METHODS
2.1

Tyrosinemia Type I mice
The Fah1RTyrC/RJ mice (Stock# 018129) from Jackson Labs (Bar Harbor, Maine,

USA) were used for the experimental cohorts and originally genetically modified at Oak
Ridge National Laboratories (Aponte et al. 2001). These Fah1R mice have no functional
expression of the protein Fah and are referred to as Fahmut mice (Hillgartner et al. 2016).
The mice were housed with 2-5 mice per cage and were kept on a 12 h reversed
light/dark cycle. The mice cages contained corn cob bedding (Harlan) as well as mouse
wheels, houses, and cotton nesting material. Mice were fed a normal protein diet mouse
chow (Teklad Global 18% Protein Rodent Diet which contains 0.6% tyrosine and 1%
phenylalanine) and water ad libitum.
The mice used in all experiments were divided into three groups, HT1 mice
Fahmut/Fahmut drinking NTBC dissolved in water (7.5 mg/L), wild-type mice drinking
NTBC dissolved in water (7.5 mg/L), and wild-type mice drinking water. The NTBC
used in the water was purchased from Yecuris Corporation (Tualatin, OR). The
Fahmut/Fahmut experimental pups require NTBC within 24 h from their mother’s breast
milk or they will die, so the pregnant dams were given NTBC in their drinking water a
few days after mating. The behavioral tests were completed using 2 cohorts of mice with
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8-10 mice per group when they were between 12 and 16 weeks old, with the mice
weaned and separated once they reached 4 weeks old. The novel object recognition test
was performed first, followed by Crawley’s three chambered sociability test. The UAH
IACUC committee approved all experimental protocols, mouse care, and breeding.

2.2

Novel Object Recognition Test
The novel object recognition test was used in order to test the memory of two

cohorts of mice with HT1 (FAHmut-NTBC), mice drinking NTBC dissolved in water
(WT-NTBC), and mice drinking water (WT-water) (Ennaceur and Delacour, 1988). An
open box apparatus 40 cm (L) x 40 cm (W) x 35 cm (H) as well as three differently
colored wooden objects was utilized for the test. The wooden objects that were used were
a star, a cube, and a trapezoid. Mice were first placed into the open box apparatus with
two objects, the cube and the star. The mice were allowed to explore the two objects for 3
minutes, and the time spent exploring each object as well as the frequency of exploration
were measured. One of the objects was then chosen at random to be replaced with the
novel object, the trapezoid, while the mouse was kept in a holding box for 2 minutes. The
mouse was then put back into the open box with the familiar object and the novel object
for 3 minutes, and the amount of time spent as well as frequency of exploration for both
objects was recorded.

2.3

Crawley’s three-chambered sociability test
The three-chambered sociability apparatus is 60 (L) x 40 (W) x 22 (H) cm and is

made up of three separate chambers, with two test chambers on either side of a middle
chamber with the internal diameter of the cage 7cm, the height 15 cm with the bars
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spaced by 7mm and 3mm in diameter (Ugo Basile, Varese, Italy). The apparatus design
was created by Moy et al. (2004) using work from Brodkin et al. (2004). The test is used
to measure the amount of time a mouse spends in each of the three chambers, as well as
the interactions the mouse has with either a dummy mouse or a real mouse and between a
familiar mouse and a novel mouse. The novel mice that were used in the experiment were
never cagemates to the test mouse and were unrelated mice of similar sex and age to the
test animal.
The mice were first placed into the center transitional chamber and allowed to
explore for 5 minutes while the doors to the left and right chambers were closed. A
transport box was then used to keep the mouse in for 1 min while a dummy mouse and a
stranger mouse were placed into small wire cages in the right and left chambers. The
doors were then opened to the left and right chambers and the mouse was allowed to
explore all three chambers for 10 min. The amount of time the mouse spent in each
chamber as well as the number of times the mouse entered each chamber was measured.
The mouse was then placed back into the transport box for 1 min while the dummy
mouse was replaced with a novel mouse. The real mouse that was used then became the
familiar mouse, and the test mouse was taken out of the transport box and placed into the
center chamber. The mouse was given 10 min to explore all three chambers, and the
amount of time spent in each chamber was recorded. The sociability test required another
two cohorts of mice due to the number of mice that had to be excluded from analysis.
Several mice had to be excluded from the test because they either climbed on top of the
wire cages or climbed on top of the apparatus.
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The amount of time the mice spent in the three chambers of the apparatus was
measured and compared between the three genotypes of mice. An Avoidance/Preference
score was also used to analyze the data, with a score of +1 given for every second the
mouse spent in the dummy mouse side and a score of -1 given for every second spent in
the real mouse side, and the time spent in the center chamber was not included in the
analysis (Brodkin et al. 2004). An overall positive score, then, indicated that a mouse
showed social avoidance and preferred to spend more time around a stuffed toy mouse
than a real mouse. An overall negative score, though, indicated that a mouse showed
normal social behavior and preferred to spend more time around an actual mouse instead
of a dummy mouse. The second part of the experiment, the novel preference test,
measured the amount of time the test mouse spent around either a familiar mouse or a
novel mouse. A positive score for this portion of this test indicated normal mouse
behavior, meaning the test mouse preferred to spend more time around a novel mouse
than a familiar mouse. A negative score for the social novelty test indicated that the test
mouse preferred to spend more time around a familiar mouse than a novel mouse, which
is abnormal mouse behavior. If the amount of time spent with the novel mouse and the
familiar mouse was similar, a score of 0 was given.

2.4

Buried Food Test
The buried food test was used to measure any differences between the olfactory

abilities of the three genotypes of mice (Yang and Crawley 2009). A teddy graham was
the novel food used and was given to the mice in their home cages two days before the
actual buried food test. The mice were fasted overnight, and all mouse chow was
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removed from the home cages and returned to the cages after the test was completed. A
clean cage (46 cm L x 23.5 cm W x 20 cm H) containing 3 cm of corn cob bedding
(Harlan) was used for each mouse. The mouse was first put into the cage and was
allowed to explore for 5 min. A transport box was then used to place the mouse into for 1
min while the teddy graham was buried 2.5 cm deep in one of the corners of the cage.
The corner that the teddy graham was buried in was chosen randomly. The mouse was
then put back into the center of the cage facing a random direction and was given 15 min
to find the buried teddy graham. The amount of time the mouse spent trying to find the
teddy graham (TTFTG) was recorded. Considering that mice utilize their olfactory
abilities for social behavior, any prolonged latency to find the teddy graham could
indicate altered sociability.

2.5

Myelin staining
Mice were sacrificed using a CO2 chamber and their brains were extracted and

quickly rinsed in ice cold PBS. The brains were then placed into a 10% neutral buffered
formalin for 6 days. A 70% ethanol solution was then used to rinse off any excess
formaldehyde from the whole brains before dissecting them. A coronal brain slicer (Zivic
Instruments, Pittsburgh, PA) was then used to orient the whole brains ventral-side up,
which were further sliced into thin 3-4 mm sections. The bregma zero location was
utilized as a landmark to slice the brain sections. Razor blades were placed into a sterile
water solution before they were used to slice the brains. The blades were partially
inserted into the brain slicer and moved slowly back and forth. The brains were then
sliced into sections by pressing the razor blades down completely, the blades were then
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raised from the slicer and the brain sections were removed from the blades individually
and placed into labeled cassettes for dehydration.
The brain slices in the labeled cassettes were placed into increasing
concentrations of ethanol in order to remove all of the water from the tissue. The
cassettes were placed into 70% ethanol for 15 min, 90% ethanol for 15 min, 100%
ethanol for 15 min, 100% ethanol for 15 min, 100% ethanol for 30 min, and 100%
ethanol for 20 min. The cassettes were further cleared using the clearing agent xylene,
with a total of three clearing steps. The cassettes were cleared two at a time, and were
placed into the first container of xylene for 20 min, the second container of xylene for 20
min, and the third container of xylene for 30 min. The cleared tissue sections were left
out to air dry for 5 minutes and then put into new labeled cassettes for paraffinization.
The tissue sections were paraffinized by using a mold to place the slices into, with
strips of paper containing the information of each tissue section attached to the bottom of
the mold to keep track of the slices. A small amount of paraffin wax was first poured into
the bottom of the mold and the tissue sections were placed on top of it. A tissue
embedding ring was then put on top of the mold and paraffin wax was added until it was
level with the top of the ring. The molds were further placed onto a cold metal pan and
allowed to chill, once the wax was hardened the paraffin blocks were taken out of the
molds and sectioned.
A rotary microtome Model 820 (American Optical, Buffalo, NY) was then used to
further section the paraffinized block of brain tissue into 20 µm ribbons. The ribbons
were placed into a water bath for 10 min and split up into sections to fit onto glass slides.
A small amount of chrome alum adhesive was poured into the water bath before placing
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the ribbons into it. The slices were further adhered onto glass slides and dried overnight
at 37 ºC for stain preparation.
The slides were stained first with 0.1% Luxol Fast Blue, differentiated using
0.05% Lithium Carbonate, and counterstained with 0.5% Cresyl Echt Violet (American
MasterTech Lodi, CA) (Kluver and Barrera 1953). The stoichiometric stain Luxol Fast
Blue can be used to quantify the myelination of brain tissue sections (Sholtz 1977). The
slides were first subjected to deparaffinization using 2 changes of xylene for 5 min each
change. Three changes of 100% ethanol were then used to rinse the slides for 1 min each
change. The slides were then rinsed with running DI water for 1 min. A waterbath
containing the stain Luxol Fast Blue was heated to 60 degrees Celsius and the slides were
immersed in the waterbath for 60 min. The slides were further rinsed with running DI
water for 1 min. The gray and white matter was then differentiated using 0.05% Lithium
Carbonate by dipping the slides into the solution 5 times for half a second each dip. Two
changes of 70% ethanol were then used to further differentiate the white and gray matter
by dipping the slides into the solutions for half-second dips until the myelin and nuclei
could be distinguished. After a 1 min DI water rinse, the slides were immersed into
Cresyl Echt Violet stain for 10 min followed by another DI water rinse for 10 seconds. A
70% ethanol solution was then used, dipping the slides a total of 5 times for half a second
each dip. The slides were then dehydrated by being placed into three changes of 100%
ethanol for 3 seconds each and were further cleared using a 1 min immersion in xylene
for a total of three changes. Permanent mounting media was then applied to the slides,
which were mounted under coverslips for microscopic analysis. The brain slices were
further photographed for analysis. The Luxol Fast Blue staining was further quantified
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for mean pixel intensity using Image J software (Schneider et al. 2012). The pixel color
intensity was averaged over a 250 µm square of tissue that was randomly chosen from the
cerebral cortex.

2.6

Plasma tyrosine assay
The blood was withdrawn from the mice through cardiac puncture after being

euthanized in a confined chamber containing CO2. The blood that was collected was
further centrifuged at 1500 x g for 5 min after being placed into a heparinized collection
tube. Plasma was then taken out and frozen at -20 ºC, with the plasma from all mice
taking NTBC diluted 10-fold using distilled water before it was analyzed. Tyrosine was
then measured by following manufacturer’s instructions using a colorimetric assay Kit
No. K573 (BioVision Inc. (Milpitas, CA). The samples that were collected were analyzed
in triplicate and were also averaged before data analysis.

2.7

Data acquisition and analysis
Data were acquired and exported as a spreadsheet, and further plotted using Prism

6.0 software. The data were further filmed and analyzed using Ethovision XT 9.0
Software (Noldus Information Technology Inc., Leesburg, VA). The mouse movement
was tracked using either the static or the dynamic subtraction, at a data sampling rate of
30 times per second. The tracking used the geometric animal center or three-point
tracking using the center, nose, and tail base to follow the mouse movement.
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2.8

Statistical analysis

All data are presented as mean ± SEM in the results and were plotted and analyzed using
Prism 6.0 software. A two-tailed Student’s t test was used to make a two-way comparison
and was considered significant with P < 0.05. Three-way comparisons were also made
using a one-way ANOVA, again with P < 0.05 significant. Tukey’s multiple comparisons
test were also used to perform intergroup analyses with P < 0.05 significant.
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CHAPTER THREE

RESULTS
3.1

Mice with HT1, wild-type mice drinking NTBC, and wild-type mice

drinking water all had similar weights
There was no significant difference between the average weight of mice with
tyrosinemia type I (FAHmut-NTBC), wild-type mice drinking NTBC (WT-NTBC), and
wild-type mice drinking water (WT-water) (Figure 3.1). The average weight of FAHmutNTBC mice was 30.0 ± 0.8 g (n = 14), the average weight of WT-NTBC mice was 26.4 ±
0.7 g (n = 10), and the average weight of WT-water mice was 27.9 ± 1.0 g (n = 8).

3.2

Mouse plasma tyrosine levels were increased tenfold with NTBC treatment
The plasma tyrosine levels were measured for FAHmut-NTBC, WT-NTBC, and

WT-water mice and found to be increased tenfold in NTBC treated mice compared to
WT-water mice (P = 0.0001) (Figure 3.2). The plasma tyrosine level for FAHmut-NTBC
mice was 1905.0 ± 85.0 µmol/L (n = 3), 1846.0 ± 42.4 µmol/L (n = 3) for WT-NTBC
mice, and 164.7 ± 21.4 µmol/L (n = 5) for WT-water mice. No difference was found
between the plasma tyrosine level of WT-NTBC and FAHmut-NTBC mice (P = 0.5676).
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Figure 3.1. Weights of male WT-Water, WT-NTBC, and FAHmut-NTBC mice are
shown with no significant difference between genotypes. No difference was found
between the weights of male mice with tyrosinemia type I drinking NTBC (FAHmutNTBC), wild-type mice drinking NTBC (WT-NTBC), and wild-type mice drinking water
(WT-water). WT-water mice had an average weight of 27.9 ± 1.0 g (n = 8), WT-NTBC
mice had an average weight of 26.4 ± 0.7 g (n = 10), and the average weight of FAHmutNTBC mice was 30.0 ± 0.8 g (n = 14).
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Figure 3.2. The plasma tyrosine levels for WT-Water, WT-NTBC, and FAHmutNTBC is shown above. The plasma tyrosine level for WT-water mice was 164.7 ± 21.4
µmol/L (n = 5), 1846.0 ± 42.4 µmol/L (n = 3) for WT-NTBC mice, and 1905.0 ± 85.0
µmol/L (n = 3) for FAHmut-NTBC mice. Treatment with NTBC increased the plasma
tyrosine level more than tenfold, with a significant difference (P < 0.0001) between WTwater mice and both groups of mice treated with NTBC, WT-NTBC and FAHmut-NTBC
mice. There was no significant difference, however, between FAHmut-NTBC mice and
WT-NTBC mice (P = 0.5676).
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3.3

Mice with HT1 show abnormal social behavior
Wild-type mice drinking water (WT-water) and wild-type mice drinking NTBC

dissolved in water (WT-NTBC) spent equal amounts of time in the chamber containing
the dummy mouse and the real mouse (Figure 3.3). WT-water mice spent 222 ± 16.67 s
(n = 8) in the chamber with the real mouse, and 201.1 ± 20.07 s (n = 8, ns, P = 0.4356) in
the chamber with the dummy mouse. WT-NTBC mice spent 250.7 ± 35.51 s (n = 9) with
the real mouse and 186.7 ± 22.46 s (n = 9, ns, P = 0.1468) with the dummy mouse. The
FAHmut-NTBC mice, though, spent almost twice as much time in the chamber with the
dummy mouse 283.1 ± 24.75 s (n = 10) than in the chamber with the real mouse 148.1 ±
23.25 s (n = 10, P = 0.0009). The FAHmut-NTBC mice spent almost 50% more time in
the chamber with the dummy mouse 283.1 ± 24.75 s (n = 10) than the WT-NTBC mice
did 186.7 ± 22.46 s (n = 9, P = 0.0108), and the WT-NTBC mice spent almost 70% more
time in the chamber with the real mouse 250.7 ± 35.51 s (n = 9) than the FAHmut-NTBC
mice did 148.1 ± 23.25 s (n = 10, P = 0.0245) (Figure 3.4). While both WT-water and
WT-NTBC mice did not discriminate between the chamber containing the dummy mouse
and the chamber with the real mouse, the FAHmut-NTBC mice showed a significant
preference for spending more time in the chamber with the dummy mouse than the
chamber with the real mouse. There was no significant difference between the time the
WT-water and WT-NTBC mice spent in either the zone with the dummy mouse and real
mouse (P = 0.5103). The amount of time the FAHmut-NTBC mice spent in the dummy
mouse side was different from both WT-water (P = 0.0131) and WT-NTBC mice (P =
0.0101), and the FAHmut-NTBC mice spent 135.1 ± 43.69 s (n = 10) more time in the
chamber with the dummy mouse than the zone with the real mouse.
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Figure 3.3. There was no significant difference in the amount of time the WT-water
and WT-NTBC mice spent in the dummy mouse zone and the amount of time spent
in the real mouse zone. The WT-water mice spent 201.1 ± 20.07 s (n = 8) in the dummy
mouse zone and 222 ± 16.67 s (n = 8, ns, P = 0.4356) in the real mouse zone. The WTNTBC mice spent 186.7 ± 22.46 s (n = 9) in the chamber with the dummy mouse, and
250.7 ± 35.51 s (n = 9, ns, P = 0.1468) in the chamber with the real mouse. The FAHmutNTBC mice did show a significant difference in the time spent between the two zones,
though, spending almost twice as much time in the dummy mouse zone. The amount of
time spent in the dummy mouse zone for the FAHmut-NTBC mice was 283.1 ± 24.75 s (n
= 10) while the amount of time spent in the real mouse zone was 148.1 ± 23.25 s (n = 10,
P = 0.0009).
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Figure 3.4. Trails of an FAHmut-NTBC and WT-NTBC mouse interacting with
either a dummy mouse or a real mouse over a 10-min trial is illustrated. The red trail
in figure A shows the interactions of the FAHmut-NTBC mouse with either the dummy
mouse which is shown on the left side of the chamber, the center chamber separating
them, and the real mouse which is shown on the right side of the chamber. The path that a
WT-NTBC mouse took over a 10-min period is shown in figure B, with the red trail
showing the mouse spent more time with the real mouse than the dummy mouse. A novel
mouse was then put into the chamber instead of the dummy mouse, and the real mouse
became the familiar mouse for the test of novel preference.
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3.4

Mice with HT1 show a lack of novelty preference
The WT-water and WT-NTBC mice displayed novel preference and spent more

time in the chamber containing the novel mouse than the chamber with the familiar
mouse (Figure 3.5). The WT-water mice spent 157 ± 16.34 s (n = 8) in the chamber with
the familiar mouse and 223.4 ± 16.58 s (n = 8, P = 0.0147) with the novel mouse. WTNTBC mice spent 153.7 ± 19.34 s (n = 9) with the familiar mouse and 259 ± 20.58 s (n =
9, P = 0.0018) with the novel mouse. There was no difference in the amount of time that
the WT-water and WT-NTBC spent in the zone with the dummy and real mouse (P =
0.7599), with the WT-water mice spending 90.7 ± 32.9 s (n = 8) and the WT-NTBC mice
spending 105.3 ± 33.2 s (n = 9) more time in the novel mouse chamber. The FAHmutNTBC mice did not display novel preference like the WT-water and WT-NTBC mice
did, however, and instead spent an equal amount of time in the chamber with the familiar
mouse 195.3 ± 19.55 s (n = 10) and in the chamber with the novel mouse 204 ± 12.51 s
(n = 10, ns, P = 0.7126) (Figure 3.6). The FAHmut-NTBC mice spent less time in the
chamber with the novel mouse 204 ± 12.51 s (n = 10) in comparison to the WT-NTBC
mice which spent 259 ± 20.58 s (n = 9, P = 0.0319). The WT-NTBC and FAHmut-NTBC
mice spent an equal amount of time in the zone with the familiar mouse, though, with the
WT-NTBC mice spending 153.7 ± 19.34 s (n =9) and the FAHmut-NTBC mice spending
195.3 ± 19.55 s (n = 10, ns, P = 0.1500). The amount of time that the FAHmut-NTBC
mice spent in either the novel or familiar mouse zone was not different, which was
significantly different from both WT-water mice (P = 0.0375) and WT-NTBC mice (P =
0.0188).
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Figure 3.5. The amount of time spent in either the novel mouse zone or familiar
mouse zone for WT-Water, WT-NTBC, and FAHmut-NTBC is shown. Novel
preference was tested for all three genotypes of mice using a novel and familiar mouse in
Crawley’s three-chambered apparatus. There was a significant difference in the amount
of time that both WT-water and WT-NTBC mice spent in the zone containing the novel
mouse and the zone with the familiar mouse. The WT-water mice spent 223.4 ± 16.58 s
(n = 8) in the zone with the novel mouse and 157 ± 16.34 s (n = 8, P = 0.0147)) in the
zone with the familiar mouse. WT-NTBC mice spent 259 ± 20.58 s (n = 9) in the zone
containing the novel mouse and spent 153.7 ± 19.34 s (n = 9, P = 0.0018) in the zone
containing the familiar mouse. No significant difference was found between the amount
of time FAHmut-NTBC mice spent in the zone with a novel mouse and the zone with a
familiar mouse. FAHmut-NTBC mice spent an equal amount of time in both chambers,
with 204 ± 12.51 s (n = 10) in the zone with the novel mouse and 195.3 ± 19.55 s (n = 10,
P = 0.7126) in the zone with the familiar mouse.
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Figure 3.6. A trail of a FAHmut-NTBC and WT-NTBC mouse interacting with either
a novel or a familiar mouse is shown. The path that was taken by a FAHmut-NTBC
mouse through the three chambers of Crawley’s apparatus is illustrated in figure A, with
the familiar mouse on the left side of the chamber and the novel mouse on the right side
of the chamber. The familiar mouse was the real mouse from the social behavior
experiment, and the novel mouse replaced the dummy mouse. The FAHmut-NTBC mouse
did not display novel preference, by instead spending equal amounts of time with the
familiar and novel mouse. The WT-NTBC mouse trail is shown in figure B, and clearly
displays novel preference by spending more time in the chamber containing the novel
mouse than the chamber with the familiar mouse.
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3.5

Mice with HT1 spent more time around a dummy mouse than a real mouse

and spent equal amounts of time around a novel and familiar mouse

An avoidance/preference score was calculated in order to analyze the data from
the three-chambered sociability test (Figure 3.7). The amount of time spent with either
the real or dummy mouse and either the familiar or novel mouse was used to create the
avoidance/preference score. Mice with HT1 displayed avoidance of the real mouse
chamber and spent more time in the chamber with the dummy mouse, with a score of
135.1 ± 43.69 s (n = 10). Both groups of wild-type mice, WT-NTBC and WT-water mice,
spent more time in the chamber with the real mouse than the chamber with the dummy
mouse with no difference between them (P = 0.5103). WT-NTBC mice had a score of 64.07 ± 53.93 s (n = 9) while WT-water mice had a score of 20.94 ± 29.99 s (n = 8) for
the social behavior portion of the test. The amount of time the FAHmut-NTBC mice spent
in the dummy mouse zone was significantly different to both WT-water (P = 0.0131) and
WT-NTBC (P = 0.0101) mice.
Mice with HT1 also showed a lack of novelty preference and spent an equal
amount of time in the chamber with the novel mouse and familiar mouse (Figure 3.7).
The two groups of wild-type mice spent more time in the chamber with the novel mouse,
though, with no difference between them (P = 0.7599). The amount of time the FAHmutNTBC mice spent in the chambers with the novel and familiar mouse was different from
WT-NTBC mice (P = 0.0188) as well as WT-water mice (P = 0.0375).

39

Figure 3.7. The avoidance/preference score for interactions with both a dummy and
a real mouse as well as a novel and familiar mouse are shown for WT-NTBC, WTWater, and FAHmut-NTBC mice. WT-water mice spent more time in the chamber with
the real mouse with a score of -20.94 ± 29.99 s (n = 8). The WT-NTBC mice also spent
more time in the chamber with the real mouse with a score of -64.07 ± 53.93 s (n = 9).
The FAHmut-NTBC mice, though, spent more time in the dummy mouse zone than the
real mouse zone, with a score of 135.1 ± 43.69 s (n = 10). Both groups of wild-type mice
spent more time in the novel mouse chamber than the familiar mouse chamber in the
novelty preference test, with no significant difference between them (P = 0.7599). The
FAHmut-NTBC mice showed no novel preference and spent equal amounts of time in the
chamber with the novel mouse and familiar mouse.
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3.6

Mice with HT1, WT-NTBC mice, and WT-water mice showed similar zone

entries as well as distance travelled in the three-chambered sociability test
The overall distance travelled during both the three-chambered sociability and
novel preference test was measured for WT-water, WT-NTBC, and FAHmut-NTBC mice
(Figure 3.8). The total distance travelled during the 5-min habituation portion of the
three-chambered sociability test was similar between WT-water, WT-NTBC, and
FAHmut-NTBC mice (F (2, 24) = 1.073, P = 0.3578). No difference was found in the total
distance travelled within the WT-water mice group (P = 0.7510), within the WT-NTBC
mice group (P = 0.4073), or within the FAHmut-NTBC mice group (P = 0.8279). The
three genotypes of mice also had similar total distances travelled within the social
behavior and novel preference test (F (5, 48) = 1.269, P = 0.2927).
The number of zone entries was also measured during the sociability and novel
preference test for all three groups of mice (Figure 3.9). The number of times that the
WT-water, WT-NTBC, and FAHmut-NTBC mice entered one of the chambers was similar
in both the sociability and novel preference test (F (11, 96) = 0.8485, P = 0.5927).
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Figure 3.8. The total distance travelled was similar for WT-water, WT-NTBC, and
FAHmut-NTBC mice. The data displays the total distance travelled for the Habituation
test (Hab), the social behavior test with the dummy and real mouse (D/R), and the
novelty preference test with the novel and familiar mouse (N/F). The total distance that
the WT-Water mice travelled was 1568 ± 168 cm (n = 8), the total distance travelled by
the WT-NTBC mice was 1308 ± 89 cm (n = 9), and the total distance travelled by the
FAHmut-NTBC mice was 1535 ± 143 cm (n = 10). There was no difference found in the
total distance travelled within the center zone of the three-chambered apparatus during
the 5-min habituation period between the three genotypes of mice (F (2, 24) = 1.073, P =
0.3578).
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Figure 3.9. There was no difference found in the number of zone entries between the
WT-water, WT-NTBC, and FAHmut-NTBC mice. The number of times the WT-water,
WT-NTBC, and FAHmut-NTBC mice entered the chambers in both the social behavior
and novel preference tests was similar (F (11, 96) = 0.8485, P = 0.5927). This can be
observed by using the FAHmut-NTBC mice as an example, with no difference between
the number of times that the FAHmut-NTBC mice entered either the Dummy mouse zone
(22.1 ± 4.1), the Real mouse zone (16.9 ± 5.5), the Novel mouse zone (18.5 ± 2.7), or the
Familiar mouse zone (18.5 ± 3.5) (F (3, 36) = 0.2889, P = 0.8331, n = 10).
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3.7

Mice with HT1, wild-type mice drinking NTBC, and wild-type mice drinking

water have similar olfactory abilities
The buried food test was used in order to analyze the olfactory abilities of WTwater, WT-NTBC, and FAHmut-NTBC mice (Figure 3.10). A piece of palatable food, a
teddy graham, was buried 2.5 cm deep in the cage bedding and the top layer of bedding
was smoothed out. The time that was taken by each genotype of mice to find the buried
teddy graham was measured and compared. There was no difference was found between
the three genotypes of mice in the time that it took to find the buried teddy graham, F (2,
16) = 0.3127, (P = 0.7359).
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Figure 3.10. The time that was spent finding the buried teddy graham is shown for
WT-Water, WT-NTBC, and FAHmut-NTBC mice. The WT-water mice took 24.4 ±
11.74 s (n = 5), the WT-NTBC mice took 36.77 ± 10.79 s (n = 6), and the FAHmut-NTBC
mice took 33.19 ± 9.367 s (n = 8) to find the buried food. There was no difference, then,
in the olfactory abilities of the WT-water, WT-NTBC, and FAHmut-NTBC mice.
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3.8

Mice with HT1 and wild-type mice drinking NTBC spend more time

investigating a novel object than a familiar object
The amount of time that the FAHmut-NTBC, WT-NTBC, and WT-water mice
spent around the novel and familiar object was measured from the novel object
recognition test (Figure 3.11). The FAHmut-NTBC and WT-NTBC mice both spent more
time around the novel object than the familiar object, while the WT-water mice spent an
equal amount of time around the novel and familiar object. There was no difference in the
amount of time that the WT-water mice spent between the novel and familiar objects, (n
= 3, ns) (Figure 3.13). The WT-NTBC mice spent twice as much time around the novel
than the familiar object, though (n = 8, P < 0.05) The FAHmut-NTBC mice also spent
almost three-fold more time investigating the novel object than the familiar object (n = 4,
P < 0.05) (Figure 3.14).
The number of times that the FAHmut-NTBC, WT-NTBC, and WT-water mice
explored both the novel and familiar object was measured and compared from the novel
object recognition test (Figure 3.12). The FAHmut-NTBC, WT-NTBC, and WT-water
mice all showed a similar number of explorations of the novel and familiar object (F (5,
28) = 1.017, P = 0.4266). There was no difference in the number of times that the
FAHmut-NTBC (n = 8), WT-NTBC (n = 5), and WT-water (n = 3) mice investigated the
novel and familiar object.
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Figure 3.11. The amount of time spent in the zone with the novel or the familiar
object is shown for WT-Water, WT-NTBC, and FAHmut-NTBC mice. The amount of
time spent in either the familiar or novel object zone was measured for WT-water, WTNTBC, and FAHmut-NTBC mice. There was no difference found in the amount of time
WT-water mice spent in the familiar and novel object zones (n = 3, ns). A significant
difference was found, though, in the amount of time that both WT-NTBC (n = 8, P <
0.05) and FAHmut-NTBC (n = 4, P < 0.05) mice spent in the familiar and novel object
zones.
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Figure 3.12. The frequency of exploration of either the novel or familiar object is
displayed for WT-Water, WT-NTBC, and FAHmut-NTBC mice. The number of times
that WT-water, WT-NTBC, and FAHmut-NTBC mice investigated both a novel and a
familiar object was measured using the novel object recognition test. There was no
significant difference in the number of times that each object was investigated for WTwater, WT-NTBC, and FAHmut-NTBC mice (F (5, 28) = 1.017, P = 0.4266).

48

Figure 3.13. An example of a trail showing a WT-water mouse interacting with
either a novel or familiar object is displayed. The number of interactions as well as
total time spent around both the novel and familiar object were measured for WT-water,
WT-NTBC, and FAHmut-NTBC mice. The novel object, the trapezoid shown on the left
side of the figure, replaced the cube from the first part of the novel object recognition
test. The WT-water mice spent an equal amount of time around the novel and familiar
object.
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Figure 3.14. An example of a trail of an FAHmut-NTBC mouse interacting with
either a novel or familiar object is shown above. The trapezoid shown on the left side
of the figure represented the novel object, which replaced the cube from the first part of
the novel object recognition test. The total amount of time spent around either the novel
or the familiar object and the frequency of exploration of both objects was recorded for
WT-water, WT-NTBC, and FAHmut-NTBC mice. The FAHmut-NTBC and WT-NTBC
both spent more time around the novel object than the familiar object.
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3.9

Mice with HT1 display increased myelination of the cerebral cortex
The FAHmut-NTBC mice brains displayed increased myelin staining of cerebral

cortex slices in comparison to WT-NTBC mice (Figure 3.15). Luxol Fast Blue was used
to stain 3-4 mm sections of cerebral cortex brain tissue from all three genotypes of mice
in order to try and observe any structural differences in myelination. Microscopic
observation of the cerebral cortex brain slices revealed increased myelination at both 1.5x
and 10x magnification.
The mean pixel intensity was calculated and used to compare the differences in
myelin staining between the three genotypes of mice (Figure 3.16). A particular 250 µm
section of cerebral cortex tissue around the lateral boundary was used to calculate the
mean pixel intensity of Luxol Fast Blue stained myelin. The WT-water mice had a mean
pixel intensity of 47.63 ± 8.35 (n = 3), the WT-NTBC mice had a mean pixel intensity of
28.46 ± 5.93 (n = 3), and the FAHmut-NTBC mice had a mean pixel intensity of 117.90 ±
11.11, n = 4, F (2, 7) = 26.31, P = 0.0006). The mean pixel intensity for the FAHmutNTBC mice was almost four times as intense as the WT-NTBC pixel intensity (P =
0.0007) and almost 3 times as intense as the WT-water pixel intensity (P = 0.0028), with
no difference between the two wild-type groups of mice (P = 0.4137).
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Figure 3.15. Cerebral cortex myelin stained with Luxol Fast Blue showed increased
myelin in mice with tyrosinemia type I compared to WT-NTBC mice. The cerebral
cortex myelination from 20 µm coronal brain slices of WT-NTBC (left) and FAHmutNTBC (right) mice is shown at 1.5x magnification in the top panels and at 10x
magnification in the bottom panels. The brain slices were taken from around bregma -1 in
both FAHmut-NTBC and WT-NTBC mice. The top panels show brain slices at 1.5x
magnification and the scale bar is 1 mm, with the bottom panels showing slices taken
from the tissue edge at 10x magnification and the scale bar at 100 µm. Increased Luxol
Fast Blue staining of myelin was observed at both magnifications of cerebral cortex
tissue of mice with tyrosinemia type I in comparison to WT-NTBC mice.

52

Figure 3.16. The mean pixel intensity of stained cerebral cortex is shown for WTWater, WT-NTBC, and FAHmut-NTBC mice. The pixel color intensity was measured
from 250 µm cerebral cortex brain slices of WT-water, WT-NTBC, and FAHmut-NTBC
mice. The intensity from FAHmut-NTBC mice was 117.9 ± 11.1 au (n = 4), more than
four times as much pixel intensity of WT-NTBC mice at 28.5 ± 5.9 au (n = 3) and more
than double the intensity of WT-water mice at 47.6 ± 8.4 au (n = 3). There was no
difference in the mean pixel intensity of the cerebral cortex tissue of WT-water and WTNTBC mice.
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CHAPTER FOUR

DISCUSSION

4.1 Abnormal Social Behavior in HT1 Mice
Tyrosinemia type I is an autosomal recessive condition that is known to produce
neurological crises (Mitchell et al. 1990), but recent studies have also shown cognitive
impairments in children with tyrosinemia type I (HT1). Recurrent neuropsychological
issues such as altered social activity, learning, and memory have been observed in
children with HT1, with the precise cause of these problems not yet established (van
Ginkel et al. 2016). In addition to this, there have been reports of lower IQ scores in
children with HT1 on NTBC treatment in comparison to healthy controls (Bendadi et al.
2014; De Laet et al. 2011). It has also been shown using the Barnes maze that the
learning and memory of tyrosinemia type I mice (FAHmut-NTBC) is deficient in
comparison to wild-type mice drinking water (WT-water) and wild-type mice drinking
NTBC (WT-NTBC) (Hillgartner et al. 2016). The social behavior of FAHmut-NTBC mice
was analyzed in comparison to WT-water and WT-NTBC mice using Crawley’s three
chambered sociability test (Moy et al. 2004) to try and uncover the source of the issues in
children with HT1. It was found that mice with tyrosinemia type I (HT1 mice) preferred
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to spend more time around a dummy mouse instead of a real mouse and spend an equal
amount of time in a chamber containing a familiar mouse and a chamber with a novel
mouse (Figure 3.7). Wild-type mice drinking water (WT-water) and wild-type mice
drinking NTBC (WT-NTBC) both spent equal amounts of time around a real mouse and
a dummy mouse, as well as more time around a novel mouse instead of a familiar mouse.
The lack of novel preference and abnormal social behavior in HT1 mice in comparison to
WT-NTBC mice suggests that these issues arise as a result of the disease process. Wildtype mice taking NTBC do not show any impairments in social behavior, which indicates
that the problems observed in children with HT1 are unlikely to be a result of NTBC
treatment.
Considering that mice normally display a high level of sociability, it is expected
that mice would want to spend more time around a real mouse over a stuffed toy, or a
dummy mouse. It is also expected that mice would prefer to investigate a novel, or new
mouse, over a familiar mouse, or a mouse that it has previously interacted with. This
behavior of spending more time around a stuffed toy is indicative of abnormal social
behavior in HT1 mice. The result of WT-NTBC mice displaying normal social behavior
in comparison to FAHmut-NTBC mice suggests that the behavior issues stem from the
disease process of tyrosinemia type I, and not from the drug treatment. The results
observed from the novel object recognition test also indicate that the treatment with
NTBC is unlikely to be the cause of the cognitive issues, since both groups of NTBCtreated mice display novel preference and spend more time around a novel object (Figure
3.11).
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4.2 Increased Myelination in HT1 Mice
The precise neurobiological source of the abnormal social behavior and cognition
in mice with tyrosinemia type I is unknown. The brains of mice with tyrosinemia type I
were extracted and observed for any noticeable alterations in myelination of the cerebral
cortex in comparison to WT-NTBC and WT-water mice to try and discover the source of
these problems. Mice with tyrosinemia type I showed an increase in myelination of the
cerebral cortex in comparison to wild-type mice (Figure 3.15). The proposed increase of
myelin in HT1 mice was further confirmed with mean pixel intensity results, which
revealed that mice with HT1 had 3 to 4 times as much myelin staining as WT-water and
WT-NTBC mice (Figure 3.16). The appropriate amount of myelin surrounding axons has
been found to be 0.6, which is defined by the g-ratio which gives a value for the ratio of
the inner axonal diameter to the outer diameter (Rushton 1951). The g-ratio is used to
describe the optimal thickness of myelin sheath surrounding axons in order to provide
proper electrical insulation for the conduction velocity of neuronal impulses. This
increase in myelin thickness indicates a decrease in g-ratio, which has been found to alter
the conduction velocity of axons and suggested to further cause abnormal behavior and
cognition (Smith and Koles 1970).
The proposed drastic increase in myelin wrapping around the axons of mice with
HT1 compared to the myelination of wild-type mice suggests that the disease process of
tyrosinemia type I has a direct effect on the myelination process of the brain. This
abnormal myelination of the cerebral cortex could lead to altered conduction velocity
along axons and further cause impaired cognition and social behavior. An abnormal
increase in the number of dendrites within a particular section of the cortex leads to a
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decrease in the amount of space available for the axons to remain functional (Chklovskii
et al. 2002). Considering that the brain has a fixed volume available, each component
must be maintained within a certain range. In the case of hypomyelination, there is an
increase of the g-ratio and the lack of sufficient myelin around axons leads to neurons
that slow conduction velocity and further impair aspects of cognition. In
hypermyelination, on the other hand, there is a decrease in g-ratio which causes abnormal
conduction velocity by creating an insufficient amount of space in the brain for the other
parts of the nervous system. Abnormal conduction velocities are further caused by either
an increase in g-ratio in the case of hypermyelination or a decrease of g-ratio in
hypomyelination (Chomiak and Hu 2009; Seidl 2014). In this way, both an increase and
decrease in myelination can cause altered conduction velocity of action potentials.
(Figure 4.1).
White matter structure is constantly remodeled during learning and throughout the
first decades of life, and the process of myelination is controlled by a variety of signaling
mechanisms as well as by neuronal activity (Ahrendsen and Macklin 2013). The white
matter of patients with HT1 has been shown to be impaired in the cerebral cortex and
globus pallidus, indicating an effect of the disease on the myelination process (Rashad
and Nassar 2011; Sener 2005). The amount of myelin that surrounds axons is dependent
upon both positive and inhibitory pathways, and it is due to the combination of these
signaling cascades that an appropriate thickness of myelin is produced. One negative
regulator of myelination, PTEN (Phosphatase and tensin homolog) works antagonistically
with the Akt/mTOR (mammalian target of rapamycin) signaling pathway to halt the
myelination process of the CNS (Macklin 2010). Another signaling cascade that is
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Figure 4.1. The relationship between axon diameter and conduction velocity is
shown, with the diameter of 0.6 the optimal value for proper velocity. Either an
increase or a decrease in axon diameter will negatively affect conduction velocity and can
further alter aspects of social behavior and cognition (Smith and Koles 1970).
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indicated to be important for CNS myelination is associated with Neuregulins (NRG-1,
NRG-2, NRG-3) which are identified as EGF-like growth factors that act through the
tyrosine kinases ErbB2, ErbB3, and ErbB4 (Brinkmann et al. 2008). A hypermyelination
phenotype has been observed in mice with an overexpression of NRG-1 type I or III as
well as Akt/mTOR, which are implicated to be important for aspects of CNS myelination
(Brinkmann et al. 2008, Macklin 2010). The neuregulin type III has been shown to be
crucial for normal development of PNS myelin, and while there are several signaling
pathways that are critical for proper myelination of the CNS there is no specific cascade
that has been identified to be of most importance for the CNS (Brinkmann et al. 2008).
The abnormal myelination observed in patients with HT1 could have a basis in altered
signaling pathways that are necessary for normal CNS myelination.

4.3

Glial cell dysfunction
Glial cells must receive signals that induce myelination and signals that inhibit

myelination in order to maintain the appropriate thickness of myelin around axons
(Macklin 2010). Glial cells such as oligodendrocytes, astrocytes, and microglia have been
labelled as supporting cells to the neurons within the brain, but recently the known
functions of these cells have broadened. Glial cells have been implicated to be secondary
to neurons in CNS function and development, but make up around 50-90% of all cells in
rodent and human brains (Bercury and Macklin 2015; Domingues et al. 2016; Ullian et
al. 2001) Astrocytes in particular are the most abundant cells within the brain and are
broadly categorized into either protoplasmic astrocytes which reside in the grey matter of
the brain, or fibrous astrocytes which reside in white matter (Molofsky et al. 2012,
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Guillamon-Vivancos et al. 2012). Astrocytes are responsible for many aspects of brain
homeostasis such as the formation of the blood brain barrier, extracellular ion balance,
provision of energy and cholesterol, and synaptic formation and elimination (Chung et al.
2015; Kiray et al. 2016).
Considering the broad range of roles astrocytes play in the CNS, it is possible that
the social behavior deficits observed in HT1 patients as well as in HT1 mice could have
sources in astrocyte dysfunction. It has also been shown that FAH may be highly
expressed in astrocytes as well as in oligodendrocytes, and this would indicate a role of
FAH in the formation or maintenance of myelin (Labelle et al. 1993; Zhang et al. 2014).
Glia dysfunction has been suggested to occur in a wide range of neuropsychiatric
disorders much like white-matter abnormalities, with astrocytic dysfunction associated
with myelin impairments. Astrocytes have been found to have a direct role in the
promotion of myelination through the release of the cytokine leukemia inhibitory factor
(LIF), which is stimulated by ATP release from action potentials (Ishibashi et al. 2006;
Fields 2005). Astrocytes contain P2 receptors that are activated by the release of ATP
from axons, which then produce LIF that promotes myelination by oligodendrocytes. It
has been shown that low concentrations of LIF promote myelination, while high
concentrations can be inhibitory to myelination (Ishibashi et al. 2006). It has also been
shown that astrocytes release brain derived neurotrophic factor (BDNF) in response to
white matter brain damage and promote oligodendrogenesis (Miyamoto et al. 2015).
Myelination requires both positive and negative regulators in order to maintain an
accurate amount of myelin surrounding axons, and alterations in either the positive or
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inhibitory signals associated with astrocytes could be contributing to the cognitive defects
seen in tyrosinemia type I patients.
The brain goes through various stages of development in which synapses are
formed and weaker connections are pruned away in order to strengthen overall synaptic
connectivity. Synapses are dynamically regulated and controlled either towards formation
or elimination by a variety of cell signals and glia. Astrocytes form close associations
with synapses and thereby can closely monitor and alter synaptic formation and
transmission (Chung et al. 2015). Astrocytes grown in culture have been shown to
promote synaptogenesis through release of various soluble factors, namely
thrombospondin 1 (TSP1) and thrombospondin 2 (TSP2), through either formation of
new synapses or stabilization of existing synapses (Christopherson et al. 2005).
Astrocytes utilize both inhibitory and synaptogenesis-promoting signals in order to
regulate synaptic function. Abnormalities in any of the astrocyte-secreted signals could
lead to impairments in overall brain function and could play a role in the impairments
seen in tyrosinemia type I patients.

4.4

NTBC Treatment and Plasma Tyrosine Levels
The harmful effects of tyrosinemia type I were able to be prevented upon the

introduction of the drug NTBC. Treatment with NTBC causes hypertyrosinemia as a
result of its effect on the tyrosine metabolic pathway, in which NTBC blocks the
formation of homogentisate from 4-hydroxyphenylpyruvate. It is through this block in the
metabolic pathway that the toxic metabolites are prevented from forming, but this block
also causes an increase in tyrosine concentrations since it is prevented from being broken
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down. Treatment with NTBC has been shown to increase the mean plasma tyrosine level
tenfold in comparison to wild-type mice drinking water (Figure 3.2). Although there is no
clear evidence showing a direct toxic effect of tyrosine on the brain, it has been shown
that amino acids can cause tissue damage at high concentrations (Thimm et al. 2012).
This could in turn affect dopamine concentrations, since tyrosine is the precursor for
dopamine. Although NTBC causes increased tyrosine levels into the brain, and altered
neurotransmitters, wild-type mice receiving NTBC treatment display no apparent
differences in social behavior or myelination of the cerebral cortex indicating that on its
own, NTBC treatment has no observable effect on cognition or the myelination process.
The neuropsychological issues currently affecting patients with tyrosinemia type I
were not observed until treatment with NTBC began, indicating a possible role of this
treatment in these issues (Garcia et al. 2017). Even though these symptoms did not appear
until treatment with NTBC began, the goal for treating these patients before NTBC was
aimed at keeping them alive. Considering the short life-expectancy of patients with HT1
before NTBC treatment, it is possible that any neurocognitive problems that may have
existed before treatment were unable to be observed. The metabolites associated with
tyrosinemia type I as well as the increased tyrosine concentrations and altered
myelination could provide a source for the behavioral issues currently affecting patients
with HT1.
4.4

Conclusions
Mice with tyrosinemia type I display impaired social behavior and altered

myelination of the cerebral cortex in comparison to wild-type mice receiving NTBC
treatment. The exact neuropsychological mechanisms underlying the behavior and
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cognitive issues in tyrosinemia type I mice has yet to be specified. Considering that the
glial cells oligodendrocytes and astrocytes both have a role in the myelination process of
the central nervous system, it is possible that the altered myelination and social behavior
of mice with tyrosinemia type I has a source in glial cell dysfunction.
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